Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741234 · ClinicalTrials.gov registry record · Phase 1
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine
A Phase 1 study, sponsored by S*BIO.
- Completed
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00741234: Completed Phase 1 study, sponsored by S*BIO.
NCT00741234 is a Phase 1 study that has completed, run by S*BIO. The registered enrollment target is 85 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00741234, a Phase 1 study, has completed, sponsored by S*BIO.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with advanced hematologic malignancies. Arm C will assess the safety and tolerability of SB939 in combination with standard azacitidine therapy.
Interventions
- DRUG Azacitidine
- DRUG SB939
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT00741234 record still lists
NCT00741234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 2 interventions - of which Azacitidine is the first listed.
NCT00741234 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00741234 about?
NCT00741234 is a clinical study titled "A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine". This is an open label, dose escalation study with 3 arms (Arms A, B, and C). Arm A will assess the safety and tolerability of escalating doses of SB939 in cohorts of patients with advanced solid tumors. Arm B will assess the safety and tolerability of escalating doses in cohorts of patients with adv...
What is the current status of trial NCT00741234?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2007-04. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00741234?
The interventions under investigation include: Azacitidine (DRUG), SB939 (DRUG).
Who is sponsoring clinical trial NCT00741234?
This trial is sponsored by S*BIO, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00741234's enrollment target sits among peer trials
85 656th of 2000 higher than 1,342 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia